Toulouse Cedex 9

• A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended recruitment
  2022-503073-11-00 5 2021-02-13 Stage IIIb cardiac AL amyloidosis
• Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible … Ended recruitment
  2024-513659-34-00 9 2021-02-12 Relapsed/Refractory aggressive B-NHL
• FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis Ended recruitment
  2024-513325-23-00 4 2021-02-03 Myelofibrosis
• KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA … Ended recruitment
  2024-513252-15-00 4 2021-01-28 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
• A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended recruitment
  2023-506839-15-00 9 2020-12-21 Renal cell carcinoma
• GYNET : A randomized, multicenter, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological ac … Ended recruitment
  2024-510714-32-00 4 2020-12-10 Patiens with locally advanced/metastatic endometrial carcinoma or cerv
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended recruitment
  2022-501645-70-00 5 2020-11-25 Crohns Disease
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended recruitment
  2023-509358-72-00 5 2020-11-23 Diffuse large B-cell lymphoma
• A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast … Ended recruitment
  2024-514733-38-00 5 2020-11-03 Unresectable locally-advanced or metastatic HER2+ breast cancer
• This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in c … Ended recruitment
  2023-504491-15-00 1 2020-10-30 Human epidermal growth factor receptor (HER2)-Expressing Cancers
• Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr … Ended recruitment
  2024-515331-30-00 7 2020-10-30 Primary Central Nervous System Lymphoma (PCNSL)
• A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended recruitment
  2022-502052-30-00 5 2020-10-27 Unresectable Esophageal Squamous Cell Carcinoma
• A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex … Ended recruitment
  2023-506877-37-00 5 2020-09-28 Relapsed/Refractory Multiple Myeloma
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in … Ended recruitment
  2023-505812-39-00 5 2020-08-28 HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
• Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients Ended recruitment
  2024-516102-36-00 4 2020-07-29 Minimal Change Nephrotic Syndrom
• A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i … Ended recruitment
  2023-507236-20-00 9 2020-07-28 Follicular Lymphoma (FL)
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis Ended recruitment
  2023-503628-22-00 5 2020-07-16 Lupus Nephritis (LN)
• A global trial to determine the effectiveness and safety of ION-682884 in patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR- … Ended recruitment
  2024-514434-20-00 5 2020-06-29 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended recruitment
  2024-518318-25-00 5 2020-06-24 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended recruitment
  2024-512704-20-00 4 2020-06-22 Unresectable and/or metastatic soft-tissue sarcoma after failure of at
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha … Ended recruitment
  2023-506588-32-00 5 2020-06-12 Relapsed and Lenalidomide-Refractory Multiple Myeloma
• A study to evaluate if benralizumab may be beneficial in the treatment of Hypereosinophilic Syndrome (HES). Ended recruitment
  2023-510455-28-00 5 2020-06-10 Hypereosinophilic Syndrome (HES)
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended recruitment
  2023-506782-56-00 5 2020-03-10 RET-Mutant Medullary Thyroid Cancer

Showing 649–672 of 893 trials